Brain zapping study aims to unlock tDCS secrets
NCT ID NCT03056170
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study used a technique called transcranial direct current stimulation (tDCS) to apply a mild electrical current to the brain in 37 healthy adults. Researchers used advanced brain scans to measure changes in brain activity, connections, and dopamine levels during and after a single 30-minute session. The goal was to understand how tDCS works at a biological level, which could help improve its use as a therapy for conditions like schizophrenia.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- transcranial direct current stimulation (tDCS) device
- What this could lead to
- If successful, this study could reveal how tDCS changes brain activity and dopamine levels, helping to refine its use for conditions like schizophrenia.
- What could go wrong
- This is a small, early study in healthy volunteers, not patients. It only tests a single session, so results may not predict long-term effects or benefits for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Le Vinatier
Bron, 69500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test